Baceriophage Therapy Summit 2019
JAFRAL is proud to be sponsoring Bacteriophage Therapy Summit that will be held 25-27th of March 2019 in Boston, US.
The Phage Futures Congress 2019
JAFRAL is going to attend The Phage Futures 2019 in Washington, [...]
Gene therapy IL-12 clinical trial
JAFRAL is proud to be a GMP manufacturing partner of a consortium/project for first clinical trial on combined electrochemotherapy with gene therapy with Interleukin-12 (IL-12) to improve/enhance local and systemic response to skin tumor treatment.
Competence Center Bio-Pharm
As of June 1 2018 JAFRAL is a part of Bio-Pharm Competence Center for Biotechnology and Pharmaceuticals.
WHO: World is running out of antibiotics
On 20th September 2017, WHO launched report about antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis. Report shows a
Viruses of Microbes 2018
JAFRAL is going to attend and co-sponsor at Viruses of Microbes 2018 in Wroclaw, Poland.
Phage Therapy & Antibiotic Resistance 2018
JAFRAL is going to attend and held presentation at Phage Therapy & Antibiotic Resistance 2018 in Florence, Italy. You are welcome to meet with our representative at the conference dr. Frenk Smrekar
A patient’s legacy: Researchers work to make
Because there have not been rigorous clinical trials of phages, they can be used only on patients for whom all other options have failed.
EU Antibiotic resistance day
Combined resistance to multiple antibiotics: a growing problem in the EU [...]
First cancer gene therapy to treat leukaemia approved by
US regulators on Wednesday approved the first gene therapy against cancer - a treatment that uses a patient's own immune cells to fight leukemia - opening a new era in the fight against one of the